Kornimate/medical-research-clean huggingface dataset:
perioperative lung function monitoring after anatomic lung resections

Conditions: Lung Function Decreased; Lung Diseases; Surgery

Summary: aim of this study was to prospectively investigate the correlation between postoperative spirometry values and pulmonary complications after anatomic lung resections. in addition, the investigators compared postoperative pulmonary function changes between open and minimally invasive approaches.

all patients undergoing an anatomical lung resection at the investigators' institution were evaluated for this study. underage patients and those undergoing extended resections (including resection of the chest wall and/or diaphragm) and/or bronchoplastic procedures were excluded. in every eligible patient undergoing an anatomic lung resection, preoperative spirometry was performed using a handheld spirometer on the day before surgery and on every second day after surgery was performed until patient discharge. the absolute values of fev1 were recorded by an independent study nurse and noted on a separate sheet not available to the treating doctors. at the end of the study period fev1 values were evaluated especially with focus on their correlation with postoperative pulmonary complications (i.e. pneumonia, acute exacerbation of copd, air leak and atelectasis). furthermore lung function values of patients undergoing 'open' resections were compared with patients undergoing minimally invasive resections.

Eligibility criteria:
inclusion criteria: * patients undergoing anatomical lung resection * written informed consent exclusion criteria: * underage patients * extended resections including resection of chest wall or diaphragm * bronchoplastic resections

Keywords: lung resection lung function vats thoracotomy
evaluation of safety and efficacy of bbi-2000 in treating and preventing contact dermatitis

Conditions: Contact Dermatitis

Summary: this two cohort study (cohort a and b) is being conducted to assess the safety and efficacy of bbi-2000 for the prevention (cohort a) and treatment (cohort b) of delayed type hypersensitivity reaction.

this two cohort (cohort a and b) single-center, randomized, controlled study is being conducted to evaluate the safety and efficacy of bbi-2000 for the prevention (cohort a) and treatment (cohort b) of delayed type hypersensitivity (dth) reactions. subjects in cohort a will initially receive either pre-treatment with bbi-2000 or vehicle, on an area on the back. diphencyprone (dpcp) will then be administered, via finn chamber, to the same area on the back. the treated area will then be assessed to determine if bbi-2000 was effective in preventing a contact hypersensitivity reaction. cohort b will first be sensitized with dpcp as in cohort a. indicated regions of the back will then be challenged to illicit a dth reaction. following the challenge, indicated regions on the subject's back will be treated with either (a) bbi-2000, (b) vehicle, (c) no topical application or (d) clobetasol propionate. the efficacy of bbi-2000 will be evaluated by monitoring response of the area of contact hypersensitivity reaction.

Eligibility criteria:
inclusion criteria: * individuals aged 18 to 65 years inclusive at the time of consent, and either female of non-reproductive potential or male. * subjects must be healthy, normal volunteers per physical exam, laboratory and ekg assessments exclusion criteria: * history of contact dermatitis to medical adhesive bandages or glue. * medical history of dermatographism. * any medical condition causing immunosuppression. * prior treatment or therapies or history of sensitivity to any of the study products.

Keywords: contact treatment prevention bbi-2000 dermatitis allergic
arthrocentesis followed by prolotherapy

Conditions: TMJ Pain

Summary: we will do tmj joint lavage and followed by dextrose injection

two groups of patients one group will receive lavage with saline and other group will receive lavage then dextrose injection

Eligibility criteria:
inclusion criteria: * tmj painful joints patients healthy patients disk displacement with reduction exclusion criteria: * patients previously treated males young age group

Keywords: tmj pain
calypso pilot study: machine learning based predictions of surgical complications

Conditions: Complication of Surgical Procedure; Postoperative Infection

Summary: this is a pilot study of surgical patients whose postoperative care will be augmented with a personalized risk prediction platform (calypso app).

calypso is a software platform that uses machine learning techniques to create personalized risk predictions for postoperative complications. individual risk factors are then linked to best-practice interventions tailored to the individual patient. the investigator aims to test the hypothesis that using calypso-augmented postoperative care will reduce complication rates in patients undergoing elective general surgery. subjects undergoing surgery will be assigned to the calypso intervention in the postoperative period.

Eligibility criteria:
inclusion criteria: * \>18 years of age * undergoing elective surgery * undergoing high risk colon, rectal, pancreas, gastric surgery with predicted length of stay greater or equal to 3 days exclusion criteria: * surgeries with less than 3 days of anticipated length of stay (e.g. stoma takedown)
tranexamic acid in nasal mohs reconstruction

Conditions: Postoperative Bleeding; Skin Cancer Face

Summary: this study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered txa among patients undergoing nasal mohs reconstruction with local flaps at vumc.

tranexamic acid (txa) is an antifibrinolytic agent that acts to decrease bleeding by stabilizing the fibrin matrix involved in the clotting cascade. the use of txa has been extensively described in the literature to prevent exsanguination in trauma and in various surgical procedures, as well as for heavy menstrual bleeding and epistaxis. studies have suggested administration of txa may improve outcomes in aesthetic surgery as well, specifically regarding intraoperative bleeding and postoperative ecchymosis and hematoma formation. txa may be administered systemically, via iv or po routes, or locally, via topical application or subcutaneous injection. local administration allows for similar benefits with minimal risk of systemic effects. following facial mohs reconstruction patients often experience surgical site ecchymosis and swelling, which may be distressing, painful, prolong healing, and result in increased healthcare utilization. other complications include hematoma, wound dehiscence, and suboptimal scarring. given the growing body of literature demonstrating the benefits of txa in surgical bleeding outcomes, txa may also be beneficial in improving postoperative mohs complications and patient satisfaction. to date, no studies have investigated the use of perioperative txa specifically in nasal mohs reconstruction. this study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered txa among patients undergoing nasal mohs reconstruction with local flaps at vumc.

Eligibility criteria:
inclusion criteria: 1. adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following mohs micrographic surgery. reconstructive procedures will be performed by drs. yang or patel in the division of facial plastic surgery in the department of otolaryngology, head and neck surgery at vanderbilt university medical center. 2. no other facial plastic procedure or sinus surgery performed simultaneously. 3. lack of all the below exclusion criteria. exclusion criteria: 1. known allergy to txa 2. intracranial bleeding 3. known defective color vision 4. history of venous or arterial thromboembolism 5. history of coagulation disorder 6. active thromboembolic disease 7. severe renal impairment (diagnosis of chronic kidney disease) 8. history of acute myocardial infarction 9. history of stroke 10. history of seizure 11. history of liver failure 12. preoperative lab results indicating thrombocytopenia (platelets \<150,000), increased bleeding risk (pt over 45, inr over 1.2).

Keywords: tranexamic acid mohs reconstruction
"pecos" b-adrenergic and ppar-g stimulation upregulates lipid metabolism in human subcutaneous fat

Conditions: Obesity

Summary: this study compares four treatments to see which one causes the most weight loss, fat loss, loss of abdominal fat and improvement in blood tests like cholesterol. the four treatments are: placebo, ephedrine plus caffeine, pioglitazone, combined pioglitazone and ephedrine plus caffeine

the sympathetic nervous system, via the intracellular messenger camp and mapk activation, and thiazolidinediones via pparγ control lipid metabolism have been implicated in body weight regulation. the present study was undertaken to determine whether the simultaneous activation of these two signaling systems might synergize to exert beneficial effects on the expression of key genes involved in lipid metabolism and mitochondrial biogenesis in subcutaneous fat in healthy, non-diabetic subjects. fifty seven non-diabetic women and men were randomized into four groups: 1) placebo/placebo (pp); 2) ephedrine plus caffeine/placebo (ecp); 3) placebo/pioglitazone (ppio); 4) ephedrine plus caffeine/pioglitazone (ecpio). adipose tissue samples were obtained after 12 weeks of treatment to determine gene expression by real time rt-pcr.

Eligibility criteria:
inclusion criteria: * generally healthy * not pregnant or nursing * using adequate contraception * between 18 and 50 years of age * bmi between 30 and 35 kg/m2 exclusion criteria: * significant renal, cardiac, liver, lung or neurological disease * high blood pressure * diabetes * prior use of thiazolidinedione * prior use of beta-blockers alcohol or drug abuse * history of thrombophlebitis, vascular or blood clotting disorders * unwilling or unable to abstain from caffeinated beverages and alcohol prior to adipose tissue biopsy and metabolic rates measurements * increased liver function test at baseline * have metal objects that would interfere with the measurement of the body composition * use drugs known to affect lipid metabolism, energy metabolism or body weight * use herbal supplements containing ephedrine and/or caffeine * take chronic medication, except hormone replacement or contraception * are a woman unwilling to use effective contraception during the trial * have heart disease or history of stroke * have urinary symptoms from enlarged prostate * have gained and or lost more than 10 pounds in the last 6 month * have use a monoamine oxidase inhibitor medication in the last month * have high or low thyroid function that has not been controlled in the normal range for at least 2 months

Keywords: ucp-1 ephedrine caffeine pioglitazone
lumbopelvic biomechanical variables and tmj kinematics changes in pregnant women: a case-control study

Conditions: Pelvic Pain

Summary: the relationship between the pelvis and stomatognathic system: various rationales for the relationship between the spine or pelvis and tmj have been found. these theories include fascial, myological interrelationships, referred pain patterns and facilitating tonic neck reflexes involving inter segmental spinal pathways. a contributing mechanism could be the relationship between how tmj occlusion, head position and body posture relate to the body's natural neurological visual/vestibular righting mechanism (blum, 2004). there is a correlation between the facial axis together with the lordotic angle and the pelvic inclination, the inner gonial angle and the mandibular plane with the lordotic angle and the pelvic inclination, as well as the facial depth with the pelvic inclination showed a significant correlation (carsten et al., 2007).


Eligibility criteria:
inclusion criteria: * the age of the participants will be ranged from 20 to 40 years. their body mass index will be ranged from 20 to 25 kg/m2. they will have regular menstrual cycle. they will not receive any hormonal therapy or taking any regular drugs. exclusion criteria: * bone disease. discogenic state with radiculopathy or not. systemic disease of musculoskeletal system. any sensory problems. previous vertebral fractures. major spinal structural abnormality. major jaw abnormality. any jaw orthotics or prosthesis. missing teeth.
protocols for prevention of pph during cs in high risk group

Conditions: Atonic PPH

Summary: pph is one of the most leading causes of maternal mortality,. it means loss of 500 ml blood after vaginal delivery and 1000 ml blood after cesarean delivery. although it's preventable it represents about 27%of maternal deaths. atony is the main cause of pph. 70%of pph corresponds to uterine atony. uterotonics like oxytocin, misoprostol, ergometrine, carbetocin and combinations of these drugs can be used but until now there is no agreement on medication that can be the most effective.


Eligibility criteria:
inclusion criteria: * 1. pregnant full term\>37 w 2. maternal age 19- 40 3.physical state 1\&2 4.patient willing to enter the study exclusion criteria: * 1.who refuse to participate in study 2.immunocomprmized and patients who had contraindicated from any of drugs used 3.patients with hypersensitivity to any drug
battlefield auricular acupuncture during adult tonsillectomies and effect of post op pain and nausea

Conditions: Tonsillitis

Summary: the purpose of this study is to determine if auricular acupuncture significantly reduces post-operative pain in comparison to the standard of care. post-operative pain score will be collected by subject self-report of pain according to the numerical rating scale (nrs) (0= no pain, 10 = worst imaginable pain) up to 10 days post-operation.

design: design type: prospective, randomized control trial sample * description of the population: all adults, greater than or equal to 18 years, undergoing a tonsillectomy with or without adenoidectomy at womack army medical center are eligible for participation in the study. * sample size: 100 subjects. a target of 45 subjects per group for a total of 90 subjects, and accounting for a 10 percent drop out rate. in fiscal year 12, 92 tonsilectomies in patients over the age of 12 were performed at womack army medical center. therefore, the investigators anticipate the study will take up to 4 years to enroll 100 adult subjects. * power analysis: under the assumption of a linear time by treatment interaction, assuming subject-level randomization, five time-points, power of 80 percent, a type i error rate of 5 per cent and no attrition, to detect a 1.6 difference in pain score requires a total sample size of 90 subjects or 45 per treatment arm.

Eligibility criteria:
inclusion criteria * all adults eighteen years of age or older having a tonsillectomy with or without adenoidectomy * anesthesiologist classification one to three exclusion criteria * chronic pain syndromes or pain symptoms lasting greater than three months or taking opioids on a daily basis for greater than four months * anesthesiologist classification four * prior neck or throat surgery * allergy to gold

Keywords: auricular acupuncture pain
trial of the efficacy of intravenous immunoglobulin for treating women with unexplained secondary recurrent miscarriage

Conditions: Secondary Recurrent Miscarriage

Summary: the investigators want to test whether infusions of intravenous immunoglobulin - a blood product known to modify immune responses - in early pregnancy will increase the chance of a subsequent live birth in women with three or more miscarriages after a birth and a total of at least four miscarriages. this will be done in a trial where 82 patients will be randomly allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.


Eligibility criteria:
inclusion criteria: * 4 or more miscarriages before the end of gestational week 14 in patients with secondary recurrent miscarriages. * at least three of these must be consecutive after the previous birth * at least two of the miscarriages with the present partner. exclusion criteria: * age below 18 or above 41 years at conception * significant uterine anomalies detected by hysterosalpingography, hysteroscopy or hydrosonography. * significant chromosomal aberrations in the couple * menstrual cycle \ 35 days * presence of lupus anticoagulant or igg anticardiolipin concentration \>= 40 gpl ku/l or plasma homocystein \>= 25 microg./l by repeated measurements at 8 weeks intervals * tests positive for hiv or tests indicating carriage of hepatitis b or c * iga deficiency * allergy to albumin, ivig or one of the substances added to preserve the drugs. * presence of chronic disease, which necessitate permanent treatment with e.g. corticosteroids , non-steroidal antiinflammatory drugs, anticoagulation, simvastatin or imurel from the start of pregnancy. * less than 2 of the previous pregnancy losses documented by ultrasound or uterine curettage. * present pregnancy a result of donor insemination or egg donation. * planned administration of gestagens or estrogens from the beginning of pregnancy. * 3 or more previous ivf/icsi/fer attempts resulting in chemical pregnancy/miscarriage. * previous participation in the trial.

Keywords: recurrent miscarriage immunology intravenous immunoglobulin miscarriage
arm spasticity - non-interventional study early bird (bont treatment: initial and repeated documentation)

Conditions: Post-stroke Arm Spasticity

Summary: botulinum toxin a (bont-a) is effective and safe in alleviating post-stroke spasticity and reducing the burden of associated symptoms. the hypothesis for this non-interventional study in arm spasticity (as-nis early bird) is no significant difference between naïve and pre-treated patients. the patients will be divided in sub-groups according to the time interval between occurrence of stroke and start of treatment (early, medium and late start of treatment according to the first and third quartiles time distribution). it is hypothesized that the "early" start of treatment group will have a reduced modified ashworth scale (mas) on the elbow and wrist flexors when compared to the "late" start of treatment group.


Eligibility criteria:
inclusion criteria: * written informed consent prior to data collection * hemiparesis and clinically relevant upper limb post-stroke spasticity * treated with dysport® or with the intention to be treated with dysport® according to local smpc * bont naïve or pre-treated with any bont product exclusion criteria: * recurrent stroke * sensitivity to dysport® or to its excipients or any other contraindications as given in the local smpc for dysport®
cervical pessary for prevention of spontaneous preterm birth in singleton pregnancies with arrested preterm labor

Conditions: Preterm Birth

Summary: preterm birth (ptb) is a major cause of perinatal morbidity and mortality. worldwide, about 15 million babies are born too soon every year, causing 1.1 million deaths, as well as short- and long-term disability in countless survivors. different strategies have been studied for prevention of spontaneous ptb (sptb) in randomized controlled trials (rcts), including progesterone, cerclage, cervical pessary, as well as lifestyle modification, such as smoking cessation, diet, aerobic exercise, and nutritional supplements. most successful effort to reduce the incidence of sptb have focused on asympatomatic women with risk factors, such as prior sptb or short cervix. however, most sptb occur in symptomatic women, i.e. women with preterm labor (ptl). women with arrested ptl are at increased risk of sptb. the cervical pessary is a silicone device that has been used to prevent sptb. the leading hypotheses for its mechanisms are two: that the pessary helps to keep the cervix closed, and that the pessary changes the inclination of the cervical canal so that the pregnancy weight is not directly above the internal os. the aim of the study is to assess the efficacy of pessary in reducing preterm birth in women with arrested preterm labor


Eligibility criteria:
inclusion criteria: * singleton gestations * diagnosis of arrested ptl * 18-50 years of age * tvu cl ≤25mm at the time of randomization exclusion criteria: * multiple gestations * rupture of membranes at the time of randomization * known major fetal structural (i.e. defined as those that are lethal or require prenatal or postnatal surgery) or chromosomal abnormality * fetal death at the time of randomization * cerclage in situ at the time of randomization * pessary in situ at the time of randomization * vaginal bleeding at the time of randomization * women who are unconscious, severly ill, mentally handicapped, or under the age of 18 years * placenta previa and/or accreta * ballooning of membranes outside the cervix into the vaginal or tvu cl = 0mm at the time of randomization * painful and regular uterine contractions at the time of randomization
efficacy and safety study of complete mesocolic excision for colon cancer

Conditions: Colon Cancer; Surgery

Summary: in 2009, prof. hohenberger proposed complete mesocolic excision (cme) as standardized, in which the same principle of tme in rectal cancer has been applied to the colon. more and more surgeons pay attention to the rationality of this surgical approach. however, the clinical application researches are still few, in particular the prospective controlled study is still none. this clinical trial will compare the cme group and non-cme group to evaluate the outcome and safety of cme for apply in clinic.

materials and methods: all the patients with colon cancer will undergo elective radical operation. the observations were recorded during the operation and on the postoperative specimens. intra-operative photographs were taken at various stages, as were photographs of the postoperative specimen. according to the cme operation keypoints, all the photographs will accept third-party assessment of the expert group, while the third-party expert group will not participate in the management of patients. both of the evaluators and research doctors are double-blind state. the postoperative patients will divided into two groups according to the results of the assessment. the clinical and pathological data of the patients as well as follow-up information will be recorded and collected. 1. outcome of cme by comparison to clinicopathologic variables, and precise tissues morphometry of two groups, the prognosis, lymph nodes harvest and removal of the mesocolic area were investigated. outcomes of interest also include disease-free survival, local recurrence-free survival, recurrence rate. in addition, we analyzed the correlation between mesocolic area and height, weight, body surface area and body mass index. 2. safety of cme cme group and non-cme group were compared the differences of security, included operation time, blood loss, postoperation complications, flatus restoring time, defecation restoring time, drainage removal time, diet restoring time, drainage volume in three days after surgery, hospital deaths, the exhaust time, hospitalization time and hospitalization costs. in addition, the feasibility of cme techniques as the surgical approach of choice for elderly patients was also evaluated.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of colon cancer; * clinical stage ⅰ \~ ⅲ; * undergoing colorectal surgery for the first time; * accept laparotomy; * accept radical resection; * more than 18 years. exclusion criteria: * emergency surgery; * preoperative neoadjuvant chemoradiotherapy history; * combined with other malignant diseases; * pathological stage ⅳ patients with colon cancer.

Keywords: complete mesocolic excision colon cancer efficacy safety